> top > docs > PubMed:11826234 > annotations

PubMed:11826234 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET

Id Subject Object Predicate Lexical cue
T0 2269-2273 gene:3567 denotes IL-5
T1 2351-2380 disease:C0085129 denotes bronchial hyperresponsiveness
T2 2269-2273 gene:3567 denotes IL-5
T3 2436-2446 disease:C0004096 denotes asthmatics
T4 2278-2282 gene:3565 denotes IL-4
T5 2351-2380 disease:C0085129 denotes bronchial hyperresponsiveness
T6 2278-2282 gene:3565 denotes IL-4
T7 2436-2446 disease:C0004096 denotes asthmatics
R1 T0 T1 associated_with IL-5,bronchial hyperresponsiveness
R2 T2 T3 associated_with IL-5,asthmatics
R3 T4 T5 associated_with IL-4,bronchial hyperresponsiveness
R4 T6 T7 associated_with IL-4,asthmatics

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
11826234-10#140#144#gene3567 2269-2273 gene3567 denotes IL-5
11826234-10#149#153#gene3565 2278-2282 gene3565 denotes IL-4
11826234-10#222#251#diseaseC0085129 2351-2380 diseaseC0085129 denotes bronchial hyperresponsiveness
11826234-10#307#317#diseaseC0004096 2436-2446 diseaseC0004096 denotes asthmatics
11826234-10#222#251#diseaseC0085129 2351-2380 diseaseC0085129 denotes bronchial hyperresponsiveness
11826234-10#307#317#diseaseC0004096 2436-2446 diseaseC0004096 denotes asthmatics
11826234-8#72#76#gene3559 1795-1799 gene3559 denotes CD25
11826234-8#72#76#gene3669 1795-1799 gene3669 denotes CD25
11826234-8#98#108#diseaseC0004096 1821-1831 diseaseC0004096 denotes asthmatics
140#144#gene3567222#251#diseaseC0085129 11826234-10#140#144#gene3567 11826234-10#222#251#diseaseC0085129 associated_with IL-5,bronchial hyperresponsiveness
140#144#gene3567307#317#diseaseC0004096 11826234-10#140#144#gene3567 11826234-10#307#317#diseaseC0004096 associated_with IL-5,asthmatics
140#144#gene3567222#251#diseaseC0085129 11826234-10#140#144#gene3567 11826234-10#222#251#diseaseC0085129 associated_with IL-5,bronchial hyperresponsiveness
140#144#gene3567307#317#diseaseC0004096 11826234-10#140#144#gene3567 11826234-10#307#317#diseaseC0004096 associated_with IL-5,asthmatics
149#153#gene3565222#251#diseaseC0085129 11826234-10#149#153#gene3565 11826234-10#222#251#diseaseC0085129 associated_with IL-4,bronchial hyperresponsiveness
149#153#gene3565307#317#diseaseC0004096 11826234-10#149#153#gene3565 11826234-10#307#317#diseaseC0004096 associated_with IL-4,asthmatics
149#153#gene3565222#251#diseaseC0085129 11826234-10#149#153#gene3565 11826234-10#222#251#diseaseC0085129 associated_with IL-4,bronchial hyperresponsiveness
149#153#gene3565307#317#diseaseC0004096 11826234-10#149#153#gene3565 11826234-10#307#317#diseaseC0004096 associated_with IL-4,asthmatics
72#76#gene355998#108#diseaseC0004096 11826234-8#72#76#gene3559 11826234-8#98#108#diseaseC0004096 associated_with CD25,asthmatics
72#76#gene366998#108#diseaseC0004096 11826234-8#72#76#gene3669 11826234-8#98#108#diseaseC0004096 associated_with CD25,asthmatics

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 187-328 OBJECTIVE denotes Activated CD8 as well as CD4 T cells contribute to the production of asthma-relevant cytokines in both atopic and nonatopic childhood asthma.
T2 341-766 OBJECTIVE denotes To measure the percentages of peripheral blood CD4 and CD8 T cells expressing naïve/memory (CD45RA/CD45RO) and activation (HLA-DR, CD25) markers, as well as mRNA-encoding interleukin-4 (IL-4) and interleukin-5 (IL-5) in atopic and nonatopic childhood asthmatics and in nonasthmatic controls matched for age and atopic status; and to study the effects of inhaled glucocorticoid therapy of the asthmatics on these measurements.
T3 776-1370 METHODS denotes Peripheral blood mononuclear cells were isolated from 17 atopic and 8 nonatopic stable (not acutely ill) asthmatics aged 7 to 16 years with moderate-to-severe disease and from 15 nonasthmatic controls matched for age and atopic status. Activation markers on CD4 and CD8 T cells were measured by flow cytometry, and expression of cytokine mRNA by in situ hybridization with CD4 and CD8 T cells were isolated using magnetic beads. Measurements were repeated in 18 of the asthmatics 4 to 6 months after initiation or escalation of inhaled glucocorticoid therapy for inadequately controlled asthma.
T4 1380-2447 RESULTS denotes The percentages of CD4 T cells expressing CD45RO but not CD45RA were elevated in both asthma groups as compared with the relevant controls and were reduced in association with de novo or augmented inhaled glucocorticoid therapy. The percentages of CD8 T cells expressing both markers were not elevated in asthmatics as compared with controls. The percentages of both CD4 and CD8 T lymphocytes expressing HLA-DR and CD25 were elevated in the asthmatics as compared with controls, and significantly reduced in association with de novo or augmented inhaled glucocorticoid therapy. Elevated percentages of CD4 T cells expressing mRNA encoding IL-4 and IL-5, and CD8 T lymphocytes expressing IL-5, were found in asthmatics as compared with the controls. De novo or augmented inhaled glucocorticoid therapy was associated with significant reductions in the percentages of CD4 T cells expressing IL-5 and IL-4 mRNA, as well as improvements in lung function, symptom scores, and bronchial hyperresponsiveness to metacholine (PD20) in both the atopic and nonatopic asthmatics.
T5 2461-2859 CONCLUSIONS denotes The data are consistent with the hypothesis that both activated CD4 and CD8 T cells are associated with child asthma, and that CD4 T cells make a greater contribution to IL-4 and IL-5 synthesis. Increased dosages of inhaled glucocorticoid resulted in clinical improvement in the asthmatics along with reduced T-cell activation and cytokine mRNA expression, suggesting a possible causal association.